Patents by Inventor Peter E. Keipert

Peter E. Keipert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Amelioration of ischemic damage using synthetic oxygen carriers
    Patent number: 6679859
    Abstract: A method of ameliorating tissue damage resulting from hypoxia or ischemia by administering systemically a synthetic oxygen carrier to an individual having or suspected of having blood vessel obstruction is disclosed. A synthetic oxygen carrier in a physiologically acceptable vehicle, wherein the synthetic oxygen carrier comprises submicron sized particles capable of passing through emboli-obstructed blood vessels is also disclosed.
    Type: Grant
    Filed: July 31, 2000
    Date of Patent: January 20, 2004
    Assignee: Alliance Pharmaceutical Corp.
    Inventors: Peter E. Keipert, N. Simon Faithfull, Stephen F. Flaim, Gwen H. Rosenberg
  • Method for the treatment of organ ischemia or infarct comprising hemodilution
    Patent number: 6007774
    Abstract: A method for treating conditions associated with ischemia or infarct is disclosed which includes the steps of administering a biocompatible non-blood oxygen carrier while monitoring one or more oxygenation indices to maintain oxygenation of the patient's tissues at or above a predetermined level.
    Type: Grant
    Filed: June 18, 1998
    Date of Patent: December 28, 1999
    Assignee: Alliance Pharmaceutical Corp.
    Inventors: Nicholas Simon Faithfull, Peter E. Keipert, Duane J. Roth, Ronald M. Hopkins
  • Method of hemodilution facilitated by monitoring oxygenation status
    Patent number: 5865784
    Abstract: A method for hemodiluting a patient is disclosed which includes the steps of administering a biocompatible oxygen carrier in conjunction with surgery or organ ischemia or infarct while assessing the patient's PvO.sub.2 or other oxygenation indices, and administering to the patient additional oxygen carrier or autologous blood in response to the PvO.sub.2 value if necessary to maintain the PvO.sub.2 at or above the desired level.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 2, 1999
    Assignee: Alliance Pharmaceutical Corp.
    Inventors: Nicholas Simon Faithfull, Peter E. Keipert, Duane J. Roth, Ronald M. Hopkins
  • Fluorocarbon emulsions with reduced pulmonary gas-trapping properties
    Patent number: 5635538
    Abstract: A fluorocarbon emulsion which exhibits reduced pulmonary gas-trapping properties in species-sensitive laboratory animals is disclosed. Additionally, the fluorocarbon component(s) exhibit short organ retention time(s). The emulsion includes an aqueous phase, an emulsifier, and a fluorocarbon (or fluorocarbon composition), having a vapor pressure of less than about 8 torr to reduce pulmonary gas-trapping, and having an organ retention half life of less than about 6 weeks and more preferably less than about 3 to 4 weeks.
    Type: Grant
    Filed: March 16, 1993
    Date of Patent: June 3, 1997
    Assignee: Alliance Pharmaceutical Corp.
    Inventors: Jeffry G. Weers, Ernest G. Schutt, Timothy J. Pelura, Peter E. Keipert
  • Facilitated oxygen delivery in conjunction with hemodilution
    Patent number: 5451205
    Abstract: A method for facilitating autologous blood use by a patient facing a loss of blood, comprising the steps of removing and preferably storing a portion of the patient's blood, intravenously administering a biocompatible liquid in sufficient quantity to substantially maintain the patient's hemodynamic stability, wherein the liquid comprises an effective oxygen-delivery enhancing amount of a biocompatible synthetic oxygen carrier, after which the patient undergoes a loss of blood, and then readministering blood to the patient, preferably the stored blood. In one embodiment, the biocompatible liquid further comprises a hemodiluent and the hemodiluent is administered separately from the oxygen carrier.
    Type: Grant
    Filed: June 3, 1994
    Date of Patent: September 19, 1995
    Assignee: Alliance Pharmaceutical Corp.
    Inventors: Duane J. Roth, Peter E. Keipert, Nicholas S. Faithfull, Thomas F. Zuck, Jean G. Riess
  • Use of synthetic oxygen carriers to facilitate oxygen delivery
    Patent number: 5344393
    Abstract: A method for facilitating autologous blood use by a patient facing a loss of blood, comprising the steps of removing and preferably storing a portion of the patient's blood, intravenously administering a biocompatible liquid in sufficient quantity to substantially maintain the patient's hemodynamic stability, wherein the liquid comprises an effective oxygen-delivery enhancing amount of a biocompatible synthetic oxygen carrier, after which the patient undergoes a loss of blood, and then readministering blood to the patient, preferably the stored blood. In one embodiment, the biocompatible liquid further comprises a hemodiluent and the hemodiluent is administered separately from the oxygen carrier.
    Type: Grant
    Filed: February 28, 1992
    Date of Patent: September 6, 1994
    Assignee: Alliance Pharmaceutical Corp.
    Inventors: Duane J. Roth, Peter E. Keipert, Nicholas S. Faithfull, Thomas F. Zuck, Jean G. Riess
  • Method of hemodilution facilitated by monitoring oxygenation status
    Patent number: RE38081
    Abstract: A method for hemodiluting a patient is disclosed which includes the steps of administering a biocompatible oxygen carrier in conjunction with surgery or organ ischemia or infarct while assessing the patient's PvO2 or other oxygenation indices, and administering to the patient additional oxygen carrier or autologous blood in response to the PvO2 value if necessary to maintain the PvO2 at or above the desired level.
    Type: Grant
    Filed: February 2, 2001
    Date of Patent: April 15, 2003
    Inventors: Nicholas Simon Faithfull, Peter E. Keipert, Duane J. Roth, Ronald M. Hopkins